Skip to main content
OpenTrials
Completed

NCT Number: NCT06532435

A Clinical Study on the Effect of DHA & ARA Candy on the Cognitive Improvement in Preschool Children

The goal of this interventional study is to evaluate the effectiveness of DHA (docosahexaenoic acid) & ARA (arachidonic acid) Candy on the cognitive development of preschool children (2-6 years old). The main questions it aims to answer are:

- Does DHA & ARA Candy improve the cognitive ability in terms of Wechsler Intelligence Scale for Children 4th edition-Chinese version (WISC-IV-Chinese)?

Researchers will administer the WISC-IV-Chinese following the guidelines strictly and analyze the score to conclude whether the DHA & ARA is effective to improve the cognitive ability of preschool childchildren.

Participants will eat 1-2 candy (each contains 100mg DHA and 100mg ARA) daily for 4 consecutive weeks and take the WISC-IV-Chinese test for three times according to the protocol.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

2 year–6 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Raison Biotech Group Shanghai Lab

Shanghai, Shanghai Municipality, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must be 2-6 years old
  • Healthy children of normal development, without gender restrictions, with a male to female ratio of more than 40%;
  • During the trial period, participants agree not to take any medications, supplements, or other nutritional products containing DHA and ARA;
  • Parents or legal guardians (at least one party) have signed an informed consent form, voluntarily participating in this study and complying with the study design;
  • Willing to not participate in other interventional nutritional studies during the trial period;
  • Capable of fully understanding the nature, purpose, benefits, and potential risks and side effects of this study.

Exclusion criteria

  • Allergic to dairy products;
  • Severely intolerant to milk dairy products;
  • Unable to provide written informed consent;
  • During the screening period, or within the past two weeks, has used antibiotics;
  • Currently taking therapeutic medications;
  • The volunteer has any of the following medical histories or has been nutritionally diagnosed with any of the following diseases: significant gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory, or cardiovascular diseases, which may affect the assessment of the trial's effects;
  • Suffering from any gastrointestinal dysfunction or gastrointestinal disease. For example, but not limited to: Irritable Bowel Syndrome (IBS), enteritis, ulcerative colitis, celiac disease, irritable bowel syndrome;
  • Has a history of hospitalization within the past 3 months;
  • According to the researcher's judgment, currently frequently using medications that may affect gastrointestinal function or the immune system.

Treatment and study plan

DHA & ARA Candy

Dietary Supplement

Parpicipants need to eat 1-2 candy daily, for 4 consective weeks

Primary outcomes

  1. Change of scale of WISC-IV-Chinese asssessment in 2 weeks

    Time frame: base day 0, week 2

    Change of scale of WISC-IV-Chinese (Wechsler Intelligence Scale for Children 4th edition-Chinese version). The WISC-IV-Chinese is an individually administered and norm-referenced instrument designed to measure intelligence for Chinese children. The WISC-IV contains 10 core subtests and five additional subtests. These are summed into a four-index score and one FSIQ, which ranges from the lowest (40) to the highest (160) points.

  2. Change of scale of WISC-IV-Chinese asssessment in 4 weeks

    Time frame: base day 0, week 4

    Change of scale of WISC-IV-Chinese (Wechsler Intelligence Scale for Children 4th edition-Chinese version). The WISC-IV-Chinese is an individually administered and norm-referenced instrument designed to measure intelligence for Chinese children. The WISC-IV contains 10 core subtests and five additional subtests. These are summed into a four-index score and one FSIQ, which ranges from the lowest (40) to the highest (160) points.

Secondary outcomes

  1. Change of Conners TRS score

    Time frame: base day 0, week 2, week 4

    Change in TRS (Conners' Teacher Rating Scale, TRS ) score over time during the intervention. The Teacher Rating Scales (TRS) are used to measure adaptive and problem behaviors in the preschool or school setting. Teachers or other qualified observers can complete forms at three age levels-preschool (ages 2 to 5), child (ages 6 to 11), and adolescent (ages 12 to 21). The Conners' Teacher Rating Scale we used is a 28-item instrument used to assess children's behavior, each item has four-choice options: 0 = Not True at All (Never, Seldom), 1 = Just a Little True (Occasionally), 2 = Pretty Much True (Often, Quite a Bit), and 3 = Very Much True (Very Often, Very Frequent). The total score ranges from 0 to 54; the smaller the score, the better the behavior.

  2. Number of sick leave days

    Time frame: base day 0, week 2, week 4

    Number of sick leave days of participants during the intervention

Sponsors and collaborators

Lead sponsor

Shandong Sibote Biotechnology Co., Ltd.

Industry

Registry information

Official study title

A Clinical Study on the Effect of DHA & ARA Candy on the Cognitive Improvement in Preschool Children of 2-6 Years Old

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Aug 1, 2024
Registry last updated
Nov 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.